During #ASCO19 CREATION.co isolated the online conversations of healthcare professionals based the US, to learn how they discussed pancreatic cancer during the meeting. Our data reveals that the big story for them was AstraZeneca's POLO trial data for olaparib.

1. What US healthcare professionals
were thinking about pancreatic cancer
during #ASCO19
Pancreatic cancer HCP insights at the
American Society of Clinical Oncology #ASCO19 meeting
0

2. The big pancreatic cancer story among US HCPs at ASCO 2019 was the release of POLO data
1
CREATION Pinpoint | HCP Insights Tracking Study | Pancreatic Cancer
United States | ASCO19
Most active and influential HCPs
Anirban Maitra @Aiims1742
Gastrointestinal pathologist, Texas
Total posts: 13 Reposted by others: 14
Original posts: 9 Mentioned by others: 14
Wungki Park @W_Park_MD
Gastrointestinal oncologist, New York
Total posts: 9 Reposted by others: 4
Original Posts: 4 Mentioned by others: 4
US HCP online activity on
pancreatic cancer during ASCO
Between May 31st and June 3rd
Allyson Ocean @drallysonocean
Gastrointestinal oncologist, New York
Total posts: 13 Reposted by others: 7
Original Posts: 5 Mentioned by others: 7
Rachna Shroff @rachnatshroff
Professor of gastrointestinal oncology, Arizona
Total posts: 10 Reposted by others: 4
Original Posts: 9 Mentioned by others: 2
302posts
100original posts
105HCP authors
0
10
20
30
40
50
60
12am
4am
8am
12pm
4pm
8pm
12am
4am
8am
12pm
4pm
8pm
12am
4am
8am
12pm
4pm
8pm
12am
4am
8am
12pm
4pm
8pm
Volumeofposts
31 May 1 Jun 2 Jun 3 Jun
POLO data
released
3.30pm
2019 ASCO
ANNUAL MEETING

3. US HCPs excited about olaparib progression free survival after POLO trial data
2
CREATION Pinpoint | HCP Insights Tracking Study | Pancreatic Cancer
United States | ASCO19
0 20 40 60 80 100
mFOLFIRINOX
nab-paclitaxel
gemcitabine
olaparib
Volume of posts
US HCP pancreatic cancer product mentions
107product mentions
HCPs positively discussed ‘practice-changing’ olaparib in
response to the POLO trial data released at ASCO. However,
some HCPs raised concerns about costs as well as the
unchanged overall survival rate compared to placebo.
After the positive POLO trial data release, doctors took to
social media to encourage genetic testing for families with an
inherited risk of BRCA pancreatic cancer mutations.
In light of practice-changing POLO data on
BRCA1/2 PDAC, re-upping my plug for
@GenerateStudy http://generatestudy.org -
cascade testing for families w inherited
#PancreaticCancer risk. Pts can enroll
remotely! Poster 256b Mon 8-11 #ASCO19
@SU2Cscience @lustgartenfdn @Aiims1742
7:44 AM · 2 Jun, 2019
@MattYurgelun
Matt Yurgelun
10 Retweets 27 Likes
Gastrointestinal oncologist, US
Retweeted by 6 US HCPs
Multiple categories applied

4. HCPs engaged with content affiliated with Let’s Win! PC
3
CREATION Pinpoint | HCP Insights Tracking Study | Pancreatic Cancer
United States | ASCO19
HCPs reposted and mentioned patient
advocacy groups, with some physicians
sharing a video series from Let’s Win!
PC about patient treatment journeys.
Doctors also shared educational content
from the PeerView institute in
collaboration with Let’s win! PC
regarding the changing treatment
landscape.
#ASCO19 On @letswinpc you can read
#mytreatmentstories about many LONG-
TERM #PancreaticCancer #survivors- what
they got, what #clinicaltrial they were on,
who treated them...#hope
2:46 PM · 1 Jun, 2019
@drallysonocean
Dr. Allyson Ocean
7 Retweets 14 Likes
Gastrointestinal oncologist, US
Retweeted by 2 US HCPs
Precision medicine in #PancreaticCancer?
Dr. @MPishvaian examines how the
treatment landscape is evolving #PeerView
#ASCO19 @letswinpc [LINK]
6:10 PM · 31 May, 2019
@PeerView
PeerView
9 Retweets 23 Likes
Medical education institute
Retweeted by 5 US HCPs